All In Biotech

BLA 761145 · Janssen Biotech

Darzalex Faspro

Daratumumab and Hyaluronidase-Fihj · Injection · CD38-directed Cytolytic Antibody; Endoglycosidase

Accelerated approvalOrphan

Last checked: Nov 20, 2026Latest source record: Feb 12, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

May 1, 2020

Approved uses

9

Original approval plus efficacy supplements

Registered trials

426

89 Phase 3, 109 recruiting

FAERS reports

3,064

1,414 serious, 121 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 12, 2026.

DARZALEX FASPRO is a combination of daratumumab, a CD38-directed cytolytic antibody, and hyaluronidase, an endoglycosidase, indicated for the treatment of adult patients with: multiple myeloma in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation in newly diagnosed patients who are eligible for autologous stem cell transplant multiple myeloma in combination with bortezomib, lenalidomide, and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant multiple myeloma in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant multiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy multiple myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant multiple myeloma in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy multiple myeloma in combination with pomalidomide and dexamethasone in patients who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor multiple myeloma in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy multiple myeloma as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI...

Mechanism: CD38 is a transmembrane glycoprotein (48 kDa) expressed on the surface of hematopoietic cells, including clonal plasma cells in multiple myeloma and light chain (AL) amyloidosis, as well as other cell types. Surface CD38 has multiple functions, including receptor mediated adhesion, signaling, and modulation of cyclase and hydrolase activity. Daratumumab is an IgG1κ human monoclonal antibody (mAb) that binds to CD38 and inhibits the growth of CD38 expressing tumor cells by inducing apoptosis directly through Fc mediated cross linking as well as by immune-mediated tumor cell lysis through...

Therapeutic areas: Hematology and blood cancers

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 27, 2026 Supplement 28 · Efficacy OrphanLetterLabel
  • Nov 19, 2025 Supplement 32 · Efficacy OrphanLabelLetter
  • Nov 6, 2025 Supplement 29 · Efficacy OrphanLetterLabel
  • Jul 30, 2024 Supplement 25 · Efficacy · priority review OrphanLabelLetter
  • Nov 30, 2021 Supplement 9 · Efficacy OrphanLabelLetter
  • Jul 9, 2021 Supplement 7 · Efficacy LabelLetter
  • Jan 15, 2021 Supplement 2 · Efficacy · priority review LabelLetter
  • Jan 11, 2021 Supplement 1 · Efficacy LabelLetter
  • May 1, 2020 Original approval · Type 3 - New Dosage Form and Type 4 - New Combination Accelerated approvalOrphanLabelLetterReview
1 products under this application
  • DARZALEX FASPRO · DARATUMUMAB AND HYALURONIDASE-FIHJ 120MG · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Daratumumab" as an intervention, any sponsor and status, largest first.

All 426 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue225
  • product dose omission issue223
  • off label use210
  • rash163
  • diarrhoea141
  • nausea118
  • dyspnoea105
  • neuropathy peripheral104
  • neutropenia91
  • plasma cell myeloma90
  • death86
  • dizziness76

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20161
20191
2020105
2021328
2022511
2023521
2024556
2025570
2026471

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Darzalex Faspro (Daratumumab-Hyaluronidase-Fihj)

2024 spending

$103M

Beneficiaries

1,125

7,367 claims

Per beneficiary

$91,304

$629.75 per unit

View as table
YearSpending
2020$5,152,437
2021$17,798,801
2022$41,953,678
2023$69,656,584
2024$102,716,642

Part B: Darzalex Faspro (Daratumumab-Hyaluronidase-Fihj) · HCPCS J9144

2024 spending

$2.53B

Beneficiaries

26,517

270,709 claims

Per beneficiary

$95,426

2024 ASP limit $50.06 per unit

View as table
YearSpending
2020$0
2021$1,046,702,030
2022$1,576,370,371
2023$2,075,948,084
2024$2,530,411,475

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 323 on PubMed

Sponsor: Johnson & Johnson (Janssen)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.